argenx SE

ARGX · NYSE

$873.71−$2.06 (−0.23%)TodayMarket closed · Oct 23, 7:55 PM ET

Prev close $875.76

Latest news

NewsOct 22, 9:42 AM ET
argenx Q3 2026 Earnings Call Transcript
NewsOct 22, 1:22 AM ET
argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate
Press releaseOct 22, 1:00 AM ETGlobe Newswire
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
NewsOct 21, 3:30 PM ET
Procter & Gamble, Western Digital On Deck Thursday As Growth, AI Demand Face Test
Press releaseOct 19, 8:00 AM ETGlobe Newswire
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
Press releaseOct 12, 4:24 PM ETBusiness Wire
ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law
Press releaseOct 8, 4:34 PM ETPRNewswire
argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)
NewsOct 8, 12:03 PM ETAvi Kapoor
Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings
NewsOct 8, 8:13 AM ETVandana Singh
Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis
NewsOct 8, 8:07 AM ETAvi Kapoor
Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
Press releaseOct 8, 1:00 AM ETGlobe Newswire
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
Press releaseOct 8, 1:00 AM ETGlobe Newswire
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
Press releaseSep 29, 8:00 AM ETGlobe Newswire
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
Press releaseAug 27, 8:50 AM ETGlobe Newswire
argenx Completes Acquisition of Forte Biosciences, Inc.
NewsAug 18, 8:12 AM ETAvi Kapoor
These Analysts Boost Their Forecasts On Argenx
NewsAug 17, 1:06 PM ET
12 Health Care Stocks Moving In Monday's Intraday Session
NewsAug 17, 12:03 PM ETAvi Kapoor
Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August
NewsAug 17, 9:51 AM ETAvi Kapoor
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday
NewsAug 17, 9:22 AM ETVandana Singh
Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal
Press releaseAug 17, 6:00 AM ETBusiness Wire
Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Press releaseAug 17, 1:00 AM ETGlobe Newswire
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
NewsAug 14, 1:35 PM ET
9 Health Care Stocks Whale Activity In Today’s Session
Press releaseAug 11, 11:56 AM ETBusiness Wire
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
Press releaseAug 6, 7:48 AM ETGlobe Newswire
argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.
Press releaseJul 28, 2:15 PM ETBusiness Wire
Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX
NewsJul 27, 12:22 PM ETAvi Kapoor
Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June
NewsJul 27, 12:16 PM ETVandana Singh
Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover
NewsJul 27, 10:35 AM ETAvi Kapoor
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday
Press releaseJul 27, 1:07 AM ETBusiness Wire
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
NewsJul 23, 10:40 AM ET
argenx Q2 2026 Earnings Call: Complete Transcript
NewsJul 23, 7:11 AM ET
Earnings Scheduled For July 23, 2026
NewsJul 23, 1:18 AM ET
argenx Q2 EPS $7.32 Beats $6.24 Estimate, Sales $1.542B Beat $1.442B Estimate
Press releaseJul 23, 1:00 AM ETGlobe Newswire
argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update
NewsJun 25, 1:57 PM ETVandana Singh
Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study
NewsJun 11, 9:09 AM ETVandana Singh
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says
Press releaseMay 18, 8:34 AM ETBusiness Wire
The Biology Came First.
NewsMay 11, 1:37 PM ETVandana Singh
Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease
Press releaseApr 18, 1:00 AM ETGlobe Newswire
argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
NewsApr 6, 1:41 PM ETVandana Singh
Why Is Viridian Therapeutics Stock Sinking Monday?
Press releaseMar 6, 1:00 AM ETGlobe Newswire
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
NewsJan 6, 7:29 AM ETAvi Kapoor
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month
NewsDec 31, 10:01 AM ETNamrata Sen
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?
NewsDec 15, 10:25 AM ETVandana Singh
Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
NewsDec 15, 8:25 AM ETVishaal Sanjay
Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus
NewsDec 15, 8:06 AM ETAvi Kapoor
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Press releaseNov 5, 9:51 AM ETPRNewswire
/C O R R E C T I O N from source -- argenx Canada Inc./
NewsOct 13, 9:43 AM ETAvi Kapoor
Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday
NewsSep 26, 5:00 PM ET
Price Over Earnings Overview: argenx
NewsAug 26, 1:35 PM ETVandana Singh
Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win
NewsAug 26, 12:33 PM ETVandana Singh
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
NewsMar 20, 12:00 PM ET
P/E Ratio Insights for argenx

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

argenx Q3 2026 Earnings Call Transcript

argenx Q3 EPS $7.80 Misses $7.83 Estimate, Sales $1.751B Beat $1.664B Estimate

argenx Reports Third Quarter 2026 Financial Results and Provides Business Update

Procter & Gamble, Western Digital On Deck Thursday As Growth, AI Demand Face Test

argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026

ARGX Investors with $100,000 in Losses Have Opportunity to Join argenx SE Fraud Investigation with SBS Law

argenx Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into argenx (ARGX)

Crude Oil Gains 5%; PepsiCo Posts Upbeat Q3 Earnings

Argenx Halts Phase 3 Study in Rare Disease Following Futility Analysis

Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session

argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease

argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline

argenx Completes Acquisition of Forte Biosciences, Inc.

These Analysts Boost Their Forecasts On Argenx

12 Health Care Stocks Moving In Monday's Intraday Session

Gold Gains 1%; US Home-Builder Sentiment Edges Higher In August

H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Monday

Argenx’s Next Blockbuster? Stock Jumps 12% After Phase 3 Myositis Trial Hits Key Goal

Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis

9 Health Care Stocks Whale Activity In Today’s Session

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

argenx Announces Commencement of Tender Offer to Acquire Forte Biosciences, Inc.

Forte Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Forte Biosciences, Inc. - FBRX

Crude Oil Falls Sharply; US Durable Goods Orders Increase 0.3% In June

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks Moving Higher On Monday

argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline

argenx Q2 2026 Earnings Call: Complete Transcript

Earnings Scheduled For July 23, 2026

argenx Q2 EPS $7.32 Beats $6.24 Estimate, Sales $1.542B Beat $1.442B Estimate

argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update

Argenx Analyst Is Bullish Despite Changes To Phase 3 Myositis Study

Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says

The Biology Came First.

Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP

Why Is Viridian Therapeutics Stock Sinking Monday?

argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline

Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month

How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next?

Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit

Stock Market Today: Dow Futures, S&P 500 Advance Ahead Of Key Economic Data: iRobot, Argenx, MindWalk In Focus

Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session

/C O R R E C T I O N from source -- argenx Canada Inc./

Tesla To $300? Here Are 10 Top Analyst Forecasts For Monday

Price Over Earnings Overview: argenx

Argenx Immune Disorder Drug's Reach Could Get Much Bigger With Major Trial Win

Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data

P/E Ratio Insights for argenx